stockportfolio.pro
Stocks / COLL vs TNDM
COLL vs TNDM
Collegium Pharmaceutical, Inc. and Tandem Diabetes Care, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Collegium Pharmaceutical, Inc. (COLL) | Tandem Diabetes Care, Inc. (TNDM) | |
|---|---|---|
| Market cap | $1.1B | $1.1B |
| Revenue (latest FY) | $780.57M | $1.01B |
| Net income (latest FY) | $62.87M | $-204.71M |
| Revenue growth (5y CAGR) | 20.3% | 15.3% |
| Net margin | 8.1% | -20.2% |
| Return on equity | 20.8% | -131.9% |
| P/E ratio | 16.8 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open COLL — free Open TNDM — freeFrequently asked questions
Which is bigger, COLL or TNDM?
Collegium Pharmaceutical, Inc. is larger by market capitalization — $1.1B versus $1.1B.
Which grows faster, COLL or TNDM?
Over the last five fiscal years, Collegium Pharmaceutical, Inc. grew revenue faster — 20.3%/yr versus 15.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.